• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. SODIUM HYALURONATE (EUFLEXXA) 20 MG/2ML; ACID, HYALURONIC, INTRAARTICULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. SODIUM HYALURONATE (EUFLEXXA) 20 MG/2ML; ACID, HYALURONIC, INTRAARTICULAR Back to Search Results
Patient Problems Erythema (1840); Rash (2033)
Event Date 04/04/2024
Event Type  Injury  
Event Description
Patient had a visit on (b)(6) 2024 with the sports medicine/orthopedic surgery clinic where she was administered hyaluronic acid visco supplementation injection (eurflexxa) for the diagnosis of osteoarthritis of bilateral knees.During this injection on (b)(6), the clinic utilized gebauer's ethyl chloride mist as a local anesthetic prior to the injection.The patient returned to the clinic on (b)(6) 2024 for the 3rd dose of eurflexxa to complete the series.Prior to the 3rd injection, the patient presented with small pruritic rash and erythema at bilateral injection sites without evidence of drainage or pain.The patient noted continued improvement from previous injections.The 3rd injection was prepared with 2% chlorhexidine and ethyl chloride spray.The patient tolerated the procedure well with no complications.Reference report: mw5154138.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SODIUM HYALURONATE (EUFLEXXA) 20 MG/2ML
Type of Device
ACID, HYALURONIC, INTRAARTICULAR
Manufacturer (Section D)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
MDR Report Key19172067
MDR Text Key341133769
Report NumberMW5154137
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Pharmacist
Type of Report Initial
Report Date 04/19/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received Not provided
Initial Date FDA Received04/23/2024
Patient Sequence Number1
Treatment
GEBAUER'S ETHYL CHLORIDE MIST. GEBAUER COMPANY.
Patient Outcome(s) Other;
Patient Age68 YR
Patient SexFemale
Patient Weight81 KG
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-